Target type: biologicalprocess
Any process that activates or increases the frequency, rate or extent of potassium ion import across the plasma membrane. [GO_REF:0000058, GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:rl, GOC:TermGenie, PMID:10636900]
Positive regulation of potassium ion import across the plasma membrane is a crucial biological process that involves the coordinated action of various proteins and mechanisms to maintain cellular homeostasis. This process plays a vital role in diverse cellular functions, including membrane potential, cell volume regulation, and signal transduction. Here's a detailed description:
**1. The Role of Potassium Ions:**
Potassium ions (K+) are essential for numerous cellular processes. They contribute to maintaining the electrochemical gradient across the plasma membrane, which is critical for:
* **Action potentials:** Nerve impulse transmission and muscle contraction rely on the rapid movement of K+ ions across the plasma membrane.
* **Cell volume regulation:** K+ plays a role in balancing water movement across the membrane, ensuring proper cell volume.
* **Cellular signaling:** K+ channels are involved in signaling pathways, influencing cell growth, proliferation, and differentiation.
**2. The Plasma Membrane as a Barrier:**
The plasma membrane acts as a selective barrier, regulating the passage of molecules, including K+, into and out of the cell. This selectivity is achieved through various membrane proteins, including ion channels and transporters.
**3. Potassium Channels:**
Potassium channels are integral membrane proteins that form pores allowing K+ ions to move across the membrane down their electrochemical gradient. Different types of K+ channels exhibit distinct properties and are regulated by diverse factors:
* **Voltage-gated K+ channels:** These channels open or close in response to changes in the membrane potential.
* **Ligand-gated K+ channels:** These channels are activated by the binding of specific molecules, such as neurotransmitters or hormones.
* **Calcium-activated K+ channels:** These channels open in response to increases in intracellular calcium concentration.
**4. Potassium Transporters:**
Potassium transporters actively move K+ ions across the membrane against their electrochemical gradient, requiring energy expenditure. These transporters play a crucial role in maintaining high intracellular K+ concentrations. Examples include:
* **Na+/K+ ATPase:** This pump uses the energy from ATP hydrolysis to transport 3 Na+ ions out of the cell and 2 K+ ions into the cell. It is a major contributor to the establishment of the electrochemical gradient across the plasma membrane.
* **K+/H+ exchanger:** This transporter couples the movement of K+ ions into the cell with the movement of H+ ions out of the cell.
**5. Regulation of Potassium Import:**
The positive regulation of potassium ion import across the plasma membrane involves a complex interplay of factors:
* **Membrane potential:** Changes in membrane potential can influence the activity of voltage-gated K+ channels, affecting K+ influx.
* **Intracellular K+ concentration:** Low intracellular K+ concentrations stimulate K+ uptake, while high concentrations inhibit it.
* **Signaling pathways:** Various signaling molecules, including hormones and neurotransmitters, can activate or inhibit K+ channels and transporters.
* **Cellular stress:** Stress conditions, such as hypoxia or oxidative stress, can trigger changes in K+ transport.
**6. Implications for Health and Disease:**
Dysregulation of potassium ion import can have significant implications for health. Abnormalities in K+ homeostasis are associated with various diseases, including:
* **Heart disease:** Irregular K+ levels can disrupt heart rhythm and contribute to cardiovascular complications.
* **Neurological disorders:** Alterations in K+ balance can affect nerve function and lead to seizures, paralysis, or cognitive impairment.
* **Kidney disease:** Impaired kidney function can result in K+ imbalances, leading to electrolyte disorders.
**7. Therapeutic Targets:**
Understanding the mechanisms underlying positive regulation of potassium ion import has opened avenues for therapeutic intervention. Targeting K+ channels and transporters offers potential for treating various diseases. For example, drugs that block K+ channels are used to treat epilepsy and arrhythmias, while K+ channel openers are being investigated for treating heart failure and other conditions.'
"
Protein | Definition | Taxonomy |
---|---|---|
Sodium/potassium-transporting ATPase subunit beta-3 | A sodium/potassium-transporting ATPase subunit beta-3 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P54709] | Homo sapiens (human) |
Sodium/potassium-transporting ATPase subunit beta-2 | A sodium/potassium-transporting ATPase subunit beta-2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P14415] | Homo sapiens (human) |
Sodium/potassium-transporting ATPase subunit beta-1 | A sodium/potassium-transporting ATPase subunit beta-1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P05026] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
lansoprazole | Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers. | benzimidazoles; pyridines; sulfoxide | anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor |
omeprazole | 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole. Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. | aromatic ether; benzimidazoles; pyridines; sulfoxide | |
pantoprazole | pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2. Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER. | aromatic ether; benzimidazoles; organofluorine compound; pyridines; sulfoxide | anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; environmental contaminant; xenobiotic |
digoxigenin | digoxigenin : A hydroxy steroid that consists of 5beta-cardanolide having a double bond at the 20(22)-position as well as hydroxy groups at the 3beta-, 12beta- and 14beta-positions. It has been isolated from the plant species of the genus Digitalis. Digoxigenin: 3 beta,12 beta,14-Trihydroxy-5 beta-card-20(22)-enolide. A cardenolide which is the aglycon of digoxin. Can be obtained by hydrolysis of digoxin or from Digitalis orientalis L. and Digitalis lanata Ehrh. | 12beta-hydroxy steroid; 14beta-hydroxy steroid; 3beta-hydroxy steroid; 3beta-sterol | hapten; plant metabolite |
digoxigenin-bis(digitoxoside) | cardenolide glycoside | ||
rostafuroxin | rostafuroxin: structure in first source | ||
ouabain | cardiac glycoside : Steroid lactones containing sugar residues that act on the contractile force of the cardiac muscles. ouabain : A steroid hormone that is a multi-hydroxylated alpha-L-rhamnosyl cardenoloide. It binds to and inhibits the plasma membrane Na(+)/K(+)-ATPase (sodium pump). It has been isolated naturally from Strophanthus gratus. Ouabain: A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE. | 11alpha-hydroxy steroid; 14beta-hydroxy steroid; 5beta-hydroxy steroid; alpha-L-rhamnoside; cardenolide glycoside; steroid hormone | anti-arrhythmia drug; cardiotonic drug; EC 2.3.3.1 [citrate (Si)-synthase] inhibitor; EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; ion transport inhibitor; plant metabolite |
digitoxin | digitoxin : A cardenolide glycoside in which the 3beta-hydroxy group of digitoxigenin carries a 2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl trisaccharide chain. Digitoxin: A cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665) | cardenolide glycoside | EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor |
digoxin | digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small. Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666) | cardenolide glycoside; steroid saponin | anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; epitope |
digitoxigenin | digitoxigenin : A 5beta-cardenolide that is 5beta-cardanolide with hydroxy substituents at the 3beta- and 14beta-positions and double bond unsaturation at C(20)-C(22). Digitoxigenin: 3 beta,14-Dihydroxy-5 beta-card-20(22)enolide. A cardenolide which is the aglycon of digitoxin. Synonyms: Cerberigenin; Echujetin; Evonogenin; Thevetigenin. | 14beta-hydroxy steroid; 3beta-hydroxy steroid | |
phakellistatin 2 | phakellistatin 2: isolated from the marine sponge Phakellia carteri; structure in first source | ||
digitoxigenin monodigitoxoside | digitoxigenin monodigitoxoside: RN given refers to (ribo-3beta,5beta)-isomer | ||
evomonoside | evomonoside : A cardenolide glycoside consisting of digitoxigenin having an alpha-L-rhamnosyl moiety attached at the O(3)-position. evomonoside: a cytotoxic cardiac glycoside from Lepidium apetalum; RN refers to (3beta,5beta)-isomer | cardenolide glycoside | |
halisulfate 1 | halisulfate 1: an isocitrate lyase inhibitor sesterterpene sulfate from sponge, Hippospongia sp.; structure in first source | organic molecular entity | metabolite |